abstract |
Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL- 13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating IL-13-mediated conditions, such as lung conditions, eg allergic asthma, is described. The ligands have potent IL-13 binding kinetics. Ligands are described that are cross-reactive between human IL- 13 and one or more primate IL-13. Ligands are well expressed in prokaryotic cells. |